Technology
Products in Development
Xelcis Bio™ is advancing TRIDENT™ across a portfolio of oncology programs, with TDOX — our lead TRIDENT™ doxorubicin conjugate — as the primary preclinical asset. Each program leverages the same core platform with modality-specific payload conjugation.
Program Highlights
Each program is built on the same TRIDENT™ core platform — with modality-specific conjugation chemistry tailored to the payload class.
TDOX — TRIDENT™ Doxorubicin
TDOX is our lead preclinical program — TRIDENT™ surface-conjugated to doxorubicin via Z-Link™ self-immolative disulfide chemistry. It is designed to overcome multidrug resistance (MDR) by improving intracellular doxorubicin concentration at the tumor site while reducing systemic exposure.
Preclinical Data (3D Spheroid MDR Model)
9.5× improved cytotoxic potency vs. Doxil® (3D spheroid MDR model)
90% reduced cardiotoxicity signal vs. Doxil®
14× enhanced cellular uptake vs. Doxil® in MDR cell line
Next milestone: in vivo CDX study (H69AR MDR lung model). IND-enabling studies to follow.
lead
TRIDENT™-OT — Oligonucleotide Therapeutics
Endosomal entrapment remains a major barrier to the effective delivery of siRNA, ASO, and mRNA therapeutics. This challenge has been addressed in prior nanoparticle delivery work advanced at TransCode Therapeutics, including TTX-MC138 (a miR-10b inhibitor), which progressed through early clinical evaluation in oncology patients. These prior programs inform the design and development of TRIDENT™.
Platform Class Validation
Prior nanoparticle delivery program advanced at TransCode Therapeutics progressed through Phase 1 clinical evaluation in oncology patients. These data provide supporting context for the delivery approach informing TRIDENT™, but do not represent clinical data for TRIDENT™.
Seeking Partnership
TRIDENT™-PT — Protein / Peptide Therapeutics
TRIDENT™ unlocks cytosolic delivery of protein therapeutics — an enduring challenge in drug delivery. In proof-of-concept studies, BSA and ovalbumin (OVA) conjugates achieved efficient intracellular delivery and cytosolic release, demonstrating robust endosomal escape and validating TRIDENT™ as a platform for functional intracellular protein delivery.
Proof-of-Concept Evidence
BSA and OVA protein conjugates demonstrated efficient intracellular delivery and cytosolic release. PCT conversion filed March 2026. Architecture parallels ADC and NDC delivery approaches.
POC Completed
TRIDENT™-TPD Platform
PROTACs and molecular glues require cytosolic access to engage E3 ligases and drive targeted protein degradation. TRIDENT™ is designed to deliver these bifunctional molecules beyond the endosomal barrier. The near-term priority beyond TDOX is a PROTAC or molecular glue targeting STAT3 — an oncoprotein with validated biological rationale and no approved degrader to date.
IP Status
Provisional patent application for TRIDENT™ TPD delivery platform scheduled for filing Q2 2026.
Seeking Partnership
TRIDENT™-NDC — Nanobody-Drug Conjugates
TRIDENT™–Nanobody/Drug Conjugates (TNDCs) combine nanobody-based targeting and therapeutic payloads on the TRIDENT™ nanoparticle to enable controlled pharmacokinetics and efficient intracellular delivery. Independent conjugation preserves modularity and design flexibility. TNDCs are engineered to overcome size limitations of NDCs and to address endosomal entrapment challenges associated with both NDCs and ADCs.
De-Risking Evidence
Proof-of-concept with protein and protein conjugate delivery completed (BSA/OVA). Nanobody/NDC PCT conversion filed March 2026.
Seeking Partnership
All Programs. One Platform.
Each TRIDENT™ program leverages the same core nanoparticle platform — with modality-specific payload conjugation via Z-Link™ surface chemistry. Manufacturing, regulatory, and formulation learnings compound across programs, reducing development risk and timeline for each successive asset.
The TRIDENT™ therapeutic delivery platform and all associated therapeutic candidates — including TDOX (TRIDENT™ Doxorubicin), TRIDENT™-PROTAC, TRIDENT™ Nucleic Acid, and TRIDENT™ Nanobody/NDC — are investigational products currently in preclinical development. None of these products have been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency for safety, efficacy, or any therapeutic use. Clinical validation data referenced relate to prior nanoparticle delivery work advanced at TransCode Therapeutics and are included to demonstrate the scientific lineage and development experience that informed Xelcis Bio's proprietary TRIDENT™ platform. These clinical studies were not conducted by Xelcis Bio™ and do not represent clinical studies of TRIDENT™.